SPARC enters pact with University of California, San Francisco, Tiller Therapeutics for Pre-clinical Oncology asset
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-12-20 08:00 GMT | Update On 2024-12-20 08:00 GMT
Advertisement
Mumbai: Sun Pharma Advanced Research Company Ltd. (SPARC) has announced the signing of a binding Letter of Intent (LOI) with the University of California, San Francisco (UCSF) through the office of OTMA, and Tiller Therapeutics Inc. to license SPARC’s rights in the joint intellectual property (IP) held between SPARC and UCSF for pre-clinical oncology asset along with associated IP.
The LOI outlines the key terms of license and rights for development and commercialization by Tiller.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.